<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T13:11:49Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10459.1/469005" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10459.1/469005</identifier><datestamp>2025-11-17T19:20:08Z</datestamp><setSpec>com_2072_3622</setSpec><setSpec>col_2072_479130</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2025-11-17T19:20:08Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_10459.1_469005">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:10459.1/469005</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)~503</dc:title>
               <dc:creator>Vidal Sabanés, Maria</dc:creator>
               <dc:creator>Bonifaci, Núria</dc:creator>
               <dc:creator>Navaridas, Raúl</dc:creator>
               <dc:creator>Egea Navarro, Joaquim</dc:creator>
               <dc:creator>Encinas Martín, Mario</dc:creator>
               <dc:creator>Rodriguez-Barrueco, Ruth</dc:creator>
               <dc:creator>Silva, Jose M.</dc:creator>
               <dc:creator>Matias-Guiu, Xavier</dc:creator>
               <dc:creator>Llobet Navas, David</dc:creator>
               <dc:creator>Dolcet Roca, Xavier</dc:creator>
               <dc:description>Endometrial cancer is the most frequent type of cancer in the female reproductive tract. Loss-of-function alterations in PTEN, leading to enhanced PI3K/AKT activation, are among the most frequent molecular alterations in endometrial cancer. Increased PI3K/AKT signaling resulting from PTEN loss promotes cellular proliferation and confers resistance to TGFβ-mediated apoptosis, a key regulator of endometrial homeostasis. In this study, we have analyzed the role of miRNAs in driving these altered cellular responses. A comprehensive transcriptomic analysis of miRNA expression revealed the upregulation of several miRNAs caused by PTEN deficiency and/or TGFβ stimulation. The miR-424(322)~503 cluster drew our attention due to its involvement in regulating apoptosis and proliferation. However, miR-424(322)~503 cluster has a paradoxical role in cancer, exhibiting either oncogenic and tumor suppressive functions depending on cell type or context. To ascertain the function of miR-424(322)~503 in endometrial
carcinogenesis caused by PTEN deficiency, we generated a double Pten/miR-424(322)~503 knock-out mice. We demonstrate that loss of miR-424(322)~503 impairs proliferation of both wild type or Pten deficient endometrial organoids by interfering with growth factor and PI3K/AKT signaling. Furthermore, the absence of miR-424(322)~503 restores TGFβ-induced apoptosis, which is otherwise compromised by PTEN deficiency. In vivo, Pten/miR-424(322)~503 knock-out mice exhibit reduced endometrial cancer progression compared to Pten deficient mice through a cell-autonomous mechanism.</dc:description>
               <dc:date>2025-11-17T19:20:08Z</dc:date>
               <dc:date>2025-11-17T19:20:08Z</dc:date>
               <dc:date>2025-10</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/10459.1/469005</dc:identifier>
               <dc:relation>Reproducció del document publicat a: https://doi.org/10.1038/s41419-025-08022-z</dc:relation>
               <dc:relation>Cell Death &amp; Disease, 2025, vol. 16, núm. 1, 705</dc:relation>
               <dc:rights>cc-by, (c) Maria Vidal Sabanés et al., 2025</dc:rights>
               <dc:rights>Attribution 4.0 International</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
               <dc:publisher>Springer Nature</dc:publisher>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>